Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repurposing Ivermectin (IVM) for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL): Safety and Response to Multiple Doses of Ivermectin

NCT07286604 is registered in ClinicalTrials.gov with International Centre for Diarrhoeal Disease Research, Bangladesh as lead sponsor.

NCT NCT07286604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07286604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repurposing Ivermectin (IVM) for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL): Safety and Response to Multiple Doses of Ivermectin
Lead sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Phase
Phase 1
Overall status
Completed
Start date
March 2, 2022
Completion date
June 6, 2023
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post kala azar dermal leishmaniasis